Keywords: nccn, advocates, noxafil, ifi, cancer, patients, drugmaker
NCCN advocates Noxafil for IFI in cancer patients
Article | 26 March 2007
US drugmaker Schering-Plough says that the National Comprehensive Cancer Network (NCCN) has issued a category 1 recommendation, advocating use of Noxafil ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
